ZS112

ZS112 is an investigational gene therapy developed for the treatment of sarcopenia (muscle loss). It utilizes a recombinant adeno-associated virus (rAAV) vector to deliver a therapeutic gene directly into human skeletal muscle cells, enabling high-efficiency expression of the target gene to promote muscle growth and function. Preclinical studies in animal models (mice and monkeys) have demonstrated significant increases in muscle mass and favorable safety profiles. ZS112 is notable as the first rAAV-based gene therapy for sarcopenia to enter clinical research, with its first-in-human trial initiated at West China Hospital/Sichuan University. The drug is currently in early-stage clinical development, with ongoing evaluation of its safety and efficacy in patients with sarcopenia[1][7].

Other names

ZS112注射液